Online Consultation For PDA Closure Doctors in Turkey

Yes. Leading hospitals in Turkey are equipped with modern cardiac catheterisation labs and neonatal cardiac care units for minimally invasive PDA closure. Key technologies include high-resolution echocardiography, dedicated paediatric and neonatal cath labs, FDA/CE-approved devices such as the Amplatzer Duct Occluder, advanced neonatal and paediatric ICU support, and hybrid catheterisation–OR suites for high-risk cases.

MediGence partners with these top-tier hospitals, providing trusted access to paediatric cardiology experts and fast-track PDA closure packages for newborns, children, and adults.

Patent Ductus Arteriosus (PDA) is a congenital heart defect where a fetal blood vessel fails to close after birth. PDA closure is recommended in:

• Infants with heart failure symptoms or poor growth
• Moderate-to-large PDA with left heart enlargement or pulmonary hypertension
• Premature babies with significant hemodynamic compromise
• Adults with persistent PDA, murmur, or infective endocarditis are at risk
• Children with recurrent respiratory infections or failure to thrive

Yes. PDA closure—especially via catheter-based occluder devices—is curative in most patients. Key benefits include:

• Elimination of abnormal blood flow between the aorta and the pulmonary artery
• Resolution of symptoms such as fatigue, shortness of breath, and feeding difficulties
• Prevention of complications like endocarditis, heart failure, and pulmonary hypertension
• Normalisation of heart size and function
• Minimally invasive with quick recovery and short hospital stay

Yes. Turkey is a sought-after destination for paediatric and adult congenital heart interventions, such as PDA closure. International patients benefit from access to expert interventional cardiologists and paediatric heart teams, rapid diagnosis and intervention, even for newborns and preterm infants. They also receive support with medical visas, travel, translation, and family accommodation, as well as comprehensive ICU and recovery care, coordination of post-operative follow-up and rehabilitation.

MediGence provides full-service international patient support, including pre-negotiated PDA closure packages and a personalised care team.

Yes. Through MediGence, you can schedule a teleconsultation with an Turkish cardiologist to:

• Review fetal or postnatal echocardiogram reports
• Confirm the diagnosis and candidacy for transcatheter PDA closure
• Discuss device options
• Receive a cost estimate, hospital stay plan, and recovery timeline
• Clarify logistics, travel preparation, and pre-op requirements
• Virtual consultations help you prepare thoroughly and minimise delays in time-sensitive cases.

Turkish cardiologists who perform Patent Ductus Arteriosus (PDA) closure are usually cardiologists who specialise in congenital heart disease or interventional pediatric cardiology. They complete a six-year medical degree, followed by a three-year residency in internal medicine or paediatrics, and then a two- to three-year fellowship in adult or pediatric cardiology. In specialised heart centres or overseas, additional practical training in cardiac catheterisation and congenital interventions is conducted. Prominent hospitals frequently perform procedures like PDA closure.

Check the Turkish Medical Council and Turkish Society of Paediatric Cardiology registries to make sure an Turkish cardiologist is licensed and board-certified in paediatrics and cardiology before approving them for PDA closure. MediGence ensures all listed cardiologists are board-certified, licensed, and experienced, with transparent credentials.

Turkish hospitals use a range of globally approved PDA closure devices, tailored to the patient’s age and defect size. The choice of device is based on the patient's PDA anatomy, weight, and associated conditions. Common options include:

• Amplatzer Duct Occluder I/II
• Occlutech PDA Occluder
• Lifetech Cera occluders
• Nit-Occlud coils

The recovery process after transcatheter PDA closure is typically smooth and includes:

• 12–24 hours of observation in a cardiac step-down or NICU setting
• A short hospital stay
• Temporary medications to prevent clotting
• Follow-up echocardiograms at 1, 3, and 6 months
• Return to regular activity within a week

MediGence assists in organising follow-up schedules and coordinating second opinions if needed.